This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Athenahealth (ATHN) Beats Q3 Earnings Estimates
by Zacks Equity Research
athenahealth (ATHN) delivered earnings and revenue surprises of 10.20% and -2.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) likely to gain from strong segmental contributions in fiscal Q4.
Will Flagship Impella Drive Abiomed's (ABMD) Q2 Earnings?
by Zacks Equity Research
Abiomed (ABMD) likely to gain from flagship Impella in Q2; a competitive industry is a headwind.
Athenahealth (ATHN) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Athenahealth (ATHN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will athenahealth (ATHN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
athenahealth (ATHN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Veeva Launches Vault SiteDocs for Regulatory Documentation
by Zacks Equity Research
Veeva's (VEEV) Vault SiteDocs Platform conducts high-quality, compliant clinical trials with greater visibility to researchers.
Varian (VAR) Buys Noona to Boost Oncology Software Services
by Zacks Equity Research
Varian's (VAR) latest move provides it significant exposure to the cloud-based oncology services market.
Cerner's Millennium Platform Integrated at McLaren Hospital
by Zacks Equity Research
Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.
Athenahealth (ATHN) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Athenahealth (ATHN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to athenahealth (ATHN) for Now
by Zacks Equity Research
athenahealth (ATHN) likely to gain from focus on cloud-based healthcare services.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) likely to gain from focus on big-data based healthcare services.
Veeva's Technology Partner Joins Verix to Boost CRM Platform
by Zacks Equity Research
Veeva Systems' (VEEV) focus on cloud-based services is likely to favor the stock.
AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up
by Zacks Equity Research
AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.
4 MedTech Stocks to Counter Mounting US-China Trade Tensions
by Sweta Jaiswal
In the wake of the impact of the U.S.-China trade war on the MedTech space, we have doubled down on some stocks which offer a safe haven to investors.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Strong prospects in Sunrise EHR platform to aid Allscripts (MDRX). However, intense competition in the MedTech space is a headwind.
Cerner CommunityWorks Selected by Pershing Health System
by Zacks Equity Research
Cerner (CERN) witnesses consistent growth in the Electronic Health Record platform and Revenue Cycle Management solutions.
Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod
by Zacks Equity Research
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
Accuray's CyberKnife Manages Prostate Cancer Effectively
by Zacks Equity Research
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
Here's Why You Should Buy Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.
RTI Surgical's (RTIX) TETRAfuse Wins Spine Technology Award
by Zacks Equity Research
RTI Surgical (RTIX) to receive the Spine Technology Award from Orthopedics This Week at the NASS 33rd Annual Meeting in Los Angeles.
Boston Scientific Thrives in Urology on New LithoVue Empower
by Zacks Equity Research
Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.
Quest Diagnostics Grows in Fertility Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.
Abiomed's Impella Ensures Higher Survival Rates, Shares Up
by Zacks Equity Research
Abiomed's (ABMD) Impella successfully treats patients with cardiogenic shocks; market prospects bright.
NextGen Rides on Prospects in RCM Space, Competition Rife
by Zacks Equity Research
NextGen (NXGN) is a major player in the U.S. RCM market. However, the company faces cutthroat competition in the healthcare information systems and services market.
Here's Why You Should Invest in PRA Health (PRAH) Stock Now
by Zacks Equity Research
The CRO industry's bullish prospects currently make PRA Health (PRAH) a promising investment pick.